Josh Bliesath

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

Denis Drygin, Amy Lin, Josh Bliesath et al. · Cancer Research · 2010 · 621 citations

Life Sciences, Medicinal Chemistry, Oncology +17

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Denis Drygin, Adam Siddiqui-Jain, Sean O’Brien et al. · Cancer Research · 2009 · 594 citations

Life Sciences, Molecular Biology, Oncology +17

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner et al. · Cancer Research · 2010 · 513 citations

Medicine, Oncology, Pharmacology +16

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux et al. · ACS Medicinal Chemistry Letters · 2012 · 164 citations

Life Sciences, Oncology, Pharmacology +14